04 December 2018 | News
Lynkogen and Alteogen will also continue to partner in exploring the feasibility of other novel dual function agents utilizing Alteogen’s proprietary NexP Fusion Technology platform.
Image Courtesy- marshfieldlabs.com
South Korea based Alteogen Inc. and US based Lynkogen Inc. have announced that they have expanded the scope of their exclusive option agreement. In addition to the originally announced GLP-1 mimetic fusion proteins, Lynkogen will also acquire exclusive rights to FGF21 fusions, including dual function FGF21/GLP-1 mimetic fusion protein.
Lynkogen and Alteogen will also continue to partner in exploring the feasibility of other novel dual function agents utilizing Alteogen’s proprietary NexP Fusion Technology platform. Lynkogen will seek to raise a Series A round to fund the development of these assets.
“Effective management of Nonalcoholic steatohepatitis (NASH) patients will require simultaneously targeting multiple pathways; the NexP platform offers a potentially differentiated way to achieve sustained therapeutic concentrations of multiple short acting peptides, with the possibility for once a week or less frequent dosing,” said Arun Swaminathan, Ph.D., CEO of Lynkogen.
NASH is poised to be the leading cause of liver transplants by 2020 and the market is projected to reach over $20 Billion by 2025. Despite a significant unmet need, there are currently no approved therapeutics available for patients with NASH.